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Abstract
Background: Invasive cervical cancer (ICC) is caused by high-risk human papillomavirus types (HR-HPVs) and is usually
preceded by a long phase of intraepithelial neoplasia (CIN). Before invasion, (epi) genetic changes, potentially applicable
as molecular markers within cervical screening, occur in HPV host cells. Epigenetic alterations, such as dysregulation of
microRNA (miRNA) expression, are frequently observed in ICC. The mechanisms and role of miRNA dysregulation in
cervical carcinogenesis are still largely unknown.
Methods: We provide an overview of the studies investigating miRNA expression in relation to ICC progression,
highlighting their common outcomes and their weaknesses/strengths. To achieve this, we systematically searched
through Pubmed database all articles between January 2010 and December 2017.
Results: From the 24 studies retrieved, miR-29a and miR-21 are the most frequently down- and up-regulated in ICC
progression, respectively. Microarray-based studies show a small overlap, with miR-10a, miR-20b, miR-9, miR-16 and miR-
106 found repeatedly dysregulated. miR-34a, miR-125 and miR-375 were also found dysregulated in cervical exfoliated
cells in relation to cancer progression.
Conclusions: The pivotal role of miRNAs in ICC progression and initial development is becoming more and
more relevant. Available studies are essentially based on convenience material, entailing possible selection
bias, and frequently of small size: all these points still represent a limitation to a wide comprehension of
miRNAs relevant for ICC. The targeted approach instead of a genome-wide investigation still precludes the
identification of all the relevant miRNAs in the process. The implementation of deep sequencing on large
scale population-based studies will help to discover and validate the relation between altered miRNA
expression and CC progression for the identification of biomarkers. Optimally, once explored on a miRNome
scale, small specific miRNA signatures maybe used in the context of screening.
Keywords: Cervical cancer, Cancer progression, microRNA, Cervical intraepithelial neoplasia (CIN) lesions, HPV
infection, Microarray, qPCR
Summary
Altered microRNA expression is observed in cervical can-
cer and precancerous lesions. Reviewing the literature,
miR-29a and miR-21 are frequently dysregulated in cancer
progression. However, microarray-based studies show a
small overlap, most studies are based on convenience ma-
terial and frequently small.
Background
Invasive cervical cancer (ICC) is the fourth most common
cancer in women worldwide with an estimated 528,000
new cases and 266,000 deaths in 2012 [1]. Infection by Hu-
man Papillomavirus (HPV) is a necessary cause of ICC [2]
but the large majority of infections clear spontaneously [3].
Persistent infections can result in intraepithelial lesions,
commonly histologically classified as cervical intraepithelial
neoplasia (CIN) grade 1 to 3. About 1/3 of CIN3 progress
to invasion in 30 years [4]. CIN1 is considered as a mor-
phologic expression of HPV infection and CIN2 as a mix-
ture of CIN1 and CIN3, frequently regressing [5]. The
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mechanisms of carcinogenesis are only partly understood.
Progression to intraepithelial pre-cancers involves the dis-
ruption of cell cycle control pathways mediated by overex-
pression of the viral E6 and E7 proteins that, among other
actions, functionally inactivate the products of the RB and
p53 immuno-suppressive genes. Progression to invasion
involves the accumulation of genetic errors. The overall
process is complex and includes a number of genetic and
epigenetic alterations [6, 7].
Screening based on testing for HPV has been shown to
be more effective than cytology-based ones and to allow
longer screening intervals [8]. However, because of what
described above, the positive predictive value of HPV test-
ing for high-grade CIN is low, requiring further triage.
Cytological triage is effective [8] but entails high frequency
of colposcopy and test repeats [9]. Markers allowing to
improve this process would be very useful, so as markers
allowing to reduce the overtreatment of non-progressive
CIN2/3.
miRNAs are short non-coding RNAs that modulate gene
expression either by catalyzing mRNA cleavage or by inhi-
biting mRNA translation [10]. The mature miRNA is a sin-
gle stranded ~ 22 nucleotide RNA, sequentially processed
from a primary transcript (pri-miRNA) and the resulting
stem-loop structure (pre-miRNA) by the Drosha and Dicer
proteins, respectively [11]. miRNAs are epigenetic regula-
tors. Many miRNAs are tissue- or differentiation-specific
and their temporal expressions modulate gene expression
by pairing with complementary nucleotide sequences of
the target mRNAs [12]. miRNAs may be overexpressed or
down regulated in cancers [13] and have been associated
with genetic (e.g. deletions, amplifications and point muta-
tions) and epigenetic (histone modifications and aberrant
DNA methylation) alterations [14, 15]. Human miRNAs
are frequently located at fragile sites and chromosomal re-
gions affected in cancer. Therefore chromosomal alter-
ations are thought to represent a major mechanism
underlying altered miRNA expression in cancer, as already
demonstrated in melanoma, neuroblastoma, myeloma cell
lines and for ovarian and breast cancer [16].
Evidence from cell lines and (pre) malignant lesions sup-
ports the involvement of miRNAs at every stage of ICC
development [17–21]. However, little is still known about
the specific miRNAs involved and the mechanisms behind
their deregulation [22]. Aberrant miRNA expression
seems to result from HR-HPV infection [18]. Some
miRNA loci localize to fragile sites, where HR-HPV DNA
integration may occur. Proteins encoded by HR-HPV can
influence host miRNAs expression. HR-HPV E6 and E7
proteins modulate the expression of DNA methyltransfer-
ases, enzymes regulating gene expression by methylating
their promoter regions [22, 23].
The aim of this review is to comprehensively evaluate
the published literature focused on miRNA profiling in
relation to progression to ICC. We are aware that some
of the studies hereby reported have been recently
reviewed by others [24–26]. However, we have updated
the studies and we have provided additional information
not previously covered. In particular, we tried to identify
common miRNA profiles (up- or down-regulated miR-
NAs) that occur during the progression from normal
cervical epithelium, via different CIN lesions, to SCCs in
primary tissue or in cervical scraping. The downstream
effect on target genes of the identified miRNA signatures
and relevant pathways emerging are also briefly
explored. Finally, we also provide an overview on the
experimental approaches so far used to analyze miRNA
expression and the design of the studies, including infor-
mation on available HPV genotyping.
Methods
Literature search
We selected all studies focused on the dysregulation of
miRNA expression during progression of cervical carcino-
genesis, especially in intraepithelial lesions. Between Janu-
ary 2010 and December 2017 we systematically searched
PubMed for publications (non-review) in English initially
with “miRNA/microRNA” and “cervical cancer” as key-
words, then supplemented by “progression”, “CIN”, “pre--
cancerous lesions”, “cervical exfoliated cells”. Besides this
search, we searched literature in PubMed by using MeSH
terms (Cervical Neoplasms and MicroRNAs) with the fol-
lowing approach: “Uterine Cervical Neoplasms” [MeSH
Terms] AND (“microRNAs” [MeSH Terms] OR “micro-
RNAs” [All Fields] OR “microRNA” [All Fields]) AND
(“microRNAs” [MeSH Terms] OR “microRNAs” [All
Fields] OR “miRNAs” [All Fields]) AND (“microRNAs”
[MeSH Terms] OR “microRNAs” [All Fields] OR (“micro”
[All Fields] AND “RNA” [All Fields]) OR “micro RNA” [All
Fields]) AND (“microRNAs” [MeSH Terms] OR “micro-
RNAs” [All Fields] OR “miRNA” [All Fields]) AND (“2006/
01/01” [PDAT]: “2017/12/31” [PDAT]) AND Journal Art-
icle [ptyp] NOT Review [ptyp]. Two independent persons
investigated the literature retrieved (A.N, D.D.M.).
Several studies were excluded according to the
following criteria (one was sufficient for exclusion):
(1) non-cervical cancers considered; (2) miRNAs
searched in serum or plasma; (3) miRNAs studied
only in cellular lines or in normal versus tumor
tissue, without relation to progression from healthy to
CIN lesions to SCC; (4) miRNAs investigated only in
advanced disease, lymph node metastasis or in rela-
tion to prognosis or treatment, radiation and chemo-
therapy, or (5) studies based on functional
experiments, miRNA–related polymorphisms, miRNA
target genes, HPV or miRNA methylation, or report-
ing only computational approaches.
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Twenty four studies were identified and included in
the present review (See workflow of selection in Add-
itional file 1: Figure S1).
For each study: author (s), publication year, number
and characteristics of patients, analyzed tissue, HPV sta-
tus and profiling platform and direction (up or down
regulation) of differentially expressed miRNAs among
different lesions were recorded. The PRISMA statement
was followed for systematic reviews http://prisma-state-
ment.org/PRISMAStatement/PRISMAStatement.aspx.
miRNA target genes, gene enrichment and pathway
analysis
For miRNAs reported as dysregulated in two or more stud-
ies (separately up- or down-regulated), we searched for vali-
dated target genes using the miRWalk 2.0 database (http://
zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2) [27]. In the
majority of situations the -3p or -5p miRNA arms was not
specified in the retrieved studies, so we have arbitrarily se-
lected one of them (if present) by an additional literature
search on the most common arms explored in the cervical
cancer field, or in cancer in general. Of all the retrieved vali-
dated target genes, we excluded those overlapping between
up- and down-regulated miRNAs. Resulting lists of target
genes were tested using the Enrichr software (http://amp.
pharm.mssm.edu/Enrichr/), for their over-representation in
biological pathways. Enrichr is an integrative web-based soft-
ware application that includes gene-set libraries, available
for analysis and download [28]. In particular, for the present
research we investigated: KEGG (http://www.genome.jp/
kegg/), and Virus Mint (http://amp.pharm.mssm.edu/Har-
monizome/resource/Virus+MINT). The relevance of each
gene set enrichment was assessed by a p-value adjusted for
multiple testing based on the hypergeometric distribution.
Gene sets with probability < 5% were considered as signifi-
cantly overrepresented.
The final list of genes was also investigated in the Cer-
vical Cancer Gene Database (CCDB) [29] which reports
separately up- or down-regulated genes involved in ICC.
Results
An overview of the 24 identified studies is reported in
Table 1. Notably, some of them investigated the overall
progression from normal epithelium to ICC, while others
only focused on intraepithelial lesions. The techniques
used most frequently to evaluate miRNA expression were
i) quantitative real -time PCR (qPCR, 18 articles), based
on candidate miRNA (s) [30–47], and ii) microarray, ei-
ther by manufacturer or customized (five articles), [16,
48–51]. Only one study analyzed miRNA expression
qualitatively by reverse-transcriptase PCR (RT-PCR) [52].
Array studies widely differed for the number of miRNAs
investigated (from 202 to 875). In candidate-miRNA stud-
ies, authors analyzed only one or few miRNAs based on
literature data or their own previous studies. A few studies
performed a discovery phase (generally by arrays) with
subsequent validation by a different technique (usually
qPCR) [47, 49, 50], as recommended, for example, by
the Minimum Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE) guidelines [53].
In general, a great variability between studies can be ob-
served, both as for the number of investigated subjects/
samples (12 to 1021, most coming from convenience ma-
terial without specification of selection methods) and the
type of samples. Most studies analyzed formalin-fixed,
paraffin-embedded tissue (FFPE) or frozen (stored in RNA
later or PBS) cervical tissues. Only three studies used cer-
vical exfoliated cells [44–46]. All specimens were collected
at enrollment, before any treatment. Several studies re-
ported HPV genotyping data or at least a stratification of
samples in HPV-negative and positive but a few did not
report any information.
The studies based on microarrays are first described
and, within each, results are compared with those of
‘validation’ studies by qPCR conducted on the same
miRNAs by the same or by other authors.
The first microarray study was published by Pereira and
colleagues in 2010 [48]. Authors reported data obtained
by an array spotted in house on 281 human miRNAs in
25 independent biological samples. Authors report high
variability of miRNA expression, especially among normal
samples and could not identify miRNAs significantly up-
or down regulated in pre- or malignant vs. normal sam-
ples. In order to minimize such variability, authors pre-
pared a pool of normal samples. With such approach they
identified 21 miRNAs with statistically significant differen-
tial expression between the pool of normal samples, a
group of CIN1 and CIN3 and the SCC samples. The ex-
pression of 8 of such miRNAs (miR-26a, miR-29a,
miR-143, miR-145, miR-99a, miR-199a, miR-203,
and miR-513) progressively decreased and that of 5 miR-
NAs (miR-10a, miR-132, miR-148a, miR-196a,
andmiR-302b) progressively increased in these three
groups. Conversely, there was a decrease moving from
normal tissue to CIN followed by an increase from CIN to
SCC for six miRNAs (miR-16, miR-27a, miR-106a,
miR-142-5p, miR-197, and miR-205) and an increase
followed by a decrease in two (miR-522*(now
miR-522-5p) and miR-512-3p). No validation of the whole
results was reported.
A subsequent array study was performed by Li Y and col-
leagues on 18 tissue samples, including HPV16-positive
SSCs and CIN [49]. Out of 875 tested miRNAs, 31 (14
down-regulated and 17 up-regulated) showed significant
trends from normal epithelium to cancer. Six of them
(miR-29a, miR-92a, miR-99a, miR-155, miR-195, and
miR-375) were validated and confirmed by qPCR in 91
biopsies (24 SCCs and 24 CIN2/3, 43 normal tissue). In
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particular, the down-regulation of miR-99a and miR-29a
confirmed the results of Pereira et al. [48] just re-
ported above. miR-218 was the most significantly
down-regulated, as confirmed by the subsequent studies of
Wilting et al. [16], Zeng et al. [50] discussed below and
more recently by Jimenez-Vences [41]. In general, miR-218
was under-expressed in tissues infected by High Risk-HPV
(HR-HPV) and more in CIN2/3 than in CIN1. In another
study by Li Y and colleagues (same first name author, but a
different group from that of the array study) [31], this
miRNA also presented lower expression levels in patients
with CIN2 and CIN3 than in those with CIN1 (78 CIN pa-
tients in total). This miRNA has hundreds of target genes,
including LAMB3, which has been recognized to increase
cell migration and to promote carcinogenesis in mouse
models and in human keratinocytes [31]. Li Y and col-
leagues (of the array study [49]), also compared miRNA ex-
pression in CIN2/3 and SCCs with HPV16 infection to
normal cervical tissues without HPV infection. The two
groups showed significant difference only for miR-375 and
miR-99a. Decreasing levels of miR-375, measured by qPCR,
with more severe histology were observed also by Bierkens
and colleagues on HPV-positive frozen biopsies (6 normal
cervical squamous epithelial specimens, 13 CDKN2A-posi-
tive HG-CIN, and 9 SCCs) [52].
Finally, in the array study of Li Y and colleagues [49],
miR-100 levels were significantly lower in CIN3 than in
CIN1 and CIN2, as confirmed subsequently [16, 32]. This
result was also validated in vitro by Li BH et al. in cervical
cell lines [32]. Down-regulation of miR-100 by its specific in-
hibitor distinctly promoted cell growth, decreased cell apop-
tosis, and accelerated G2/M phase progression in HaCaT
cells that constitutively express high level of this miRNA.
These findings together suggest that a reduced miR-100 ex-
pression may contribute to cervical carcinogenesis by regu-
lating cell growth, cell cycle and apoptosis.
In a study by Cheung and colleagues, the expression of a
panel of 202 miRNAs was investigated in normal epithe-
lium, CIN2, CIN3 and ICC samples using a qPCR platform
[51]. Twelve miRNAs (10 up- and 2 down-regulated) were
differentially expressed in CIN2/3 biopsies compared to
normal cervical epithelial cells. This 12-miRNA signature
could clearly separate CIN2/3 from normal tissue in an in-
dependent group of samples (6 CIN2, 18 CIN3, 9 normal)
and patients with SCC (51) from individuals with normal
cervical epithelium but not CIN2 from CIN3. Overall,
miR-20b and miR-9 showed the highest fold change
up-regulation. miR-9 expression was also significantly
higher in SCC than in CIN2/3. Authors considered miR-9
of particular interest because it stimulates angiogenesis in
a cell-type and context-dependent manner and it is
up-regulated in several cancers [51], including ICC [48,
50]. A miR-9-mediated down-regulation of E-cadherin has
been shown to lead to activation of β-catenin, resulting in
the up-regulation of the target gene VEGFA, a proangio-
genic factor [54]. Down-regulation of E-cadherin has been
observed in both CIN and SCC and this is consistent with
the progressive up-regulation of miR-9 in CIN and SCC
described above [51].
Wilting and colleagues [16] investigated by a microarray
the expression of 472 human miRNAs in 47 subjects (nor-
mal epithelium, CIN2/3, SCCs) and correlated their differ-
ential expression to histology. In total, 106 miRNAs were
differentially expressed in CIN2/3 and/or SCCs compared
with normal epithelium. Authors identified early transient
miRNAs (n = 27; with significantly different expression in
CIN2/3 compared to normal epithelia but with no differ-
ence in SCCs vs. normal), late miRNAs (n = 46; miRNAs
having differential expression in SCCs compared with nor-
mal tissue and CIN2/3, but not in CIN2/3 compared with
normal tissue), and early continuous miRNAs (n = 33;
those molecules showing concordant differential expres-
sion in SCCs and CIN2/3 compared with normal) (details
in Table 1). Some of the altered miRNA expression levels
confirmed the results by Pereira et al. [48] and by Cheung
et al. [51] (for instance miR-10a up-regulation and
miR-203 down-regulation) and by a more recent study of
Gocze and colleagues [36]. The latter group also confirmed
Wilting` s observations of an increase of miR-155 in the
transition from CIN1 to SCC, so as Li et al. [16, 49].
More recently, Zeng and colleagues [50] compared
miRNA expression profiles in ICC, CIN and normal cervical
tissues by microarray analysis and found several miRNAs as
significantly dysregulated. In particular, 16 miRNAs were
up-regulated and 10 were significantly down-regulated when
comparing SCC to normal tissue. miR-21, miR-21-3p
(formerly miR-21*), miR-15b and miR-16 were the most
over-expressed while miR-218 and miR-376 were the most
down-regulated. Forty four miRNAs were differentially
expressed (13 up- and 31 down-regulated) when CIN2/3
were compared to normal cervical tissue. No significantly
differentially expressed miRNAs were found when compar-
ing CIN1 to normal tissue. Nine miRNAs (miR-21,
miR-218, miR-376a, miR-31, miR-630, miR-9, miR-195,
miR-497, and miR-199b-5p) differentially expressed in cer-
vical samples with and without lesions were validated by
qPCR in 103 samples with similar characteristics. miR-21,
miR-31 and miR-9 were again significantly up-regulated in
ICC, as found in other works reported in the present review
[16, 33, 36, 37, 49, 51]. Among the other validated results,
miR-218, miR-195, miR-497 and miR-199b-5p were signifi-
cantly down-regulated in ICC and CIN2/3, while miR-376a
was significantly down-regulated only in ICC but not in
CIN2/3. However, they did not observe differential miRNA
expression between CIN1 and normal tissue, Authors hy-
pothesized that miRNAs down-regulated in both SCC and
CIN2/3 may be involved in the abnormal transformation
from pre-cancerous lesions to cancer.
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Other studies investigated one or few miRNAs previ-
ously identified as dysregulated in ICC progression.
Villegas-Ruiz and colleagues [47] after an initial investi-
gation of miRNA profiles in tumor vs. healthy tissue by
arrays, focused on the expression of miR-196a in relation
to ICC progression. They showed increasing expression
of this miRNA from healthy tissues to low grade and to
high grade CIN and tumor, confirming the findings of
Pereira et al. In the study of Gocze [36], miR-196a also
showed an increasing expression from CIN1 to CIN2/3
but was significantly lower in SCC than in CIN2/3.
Deftereos et al. [33] analyzed miR-143 and miR-21 in a
large set of samples with different stages of disease. Despite
increasing down-regulation of miR-143 with increasing
severity of histology had been previously reported [47, 48],
such pattern was not confirmed in this study [33]. miR-21
expression had been observed to increase with more severe
diagnosis in neoplasms of many sites. An overexpressed
miR-21 was also found in cervical pre-cancerous lesions
and in ICC [16, 36, 37, 40]. In the work of Deftereos et al.
[33] its levels increased from low-to high-grade CIN and
were highest in invasive cancer tissues. miR-21 was also an-
alyzed by Shishoida and colleagues together with let-7a
[37]. Increasing miR-21 expression levels were found asso-
ciated with disease progression while lower levels of let-7a
were detected in invasive cancer tissues compared to
pre-cancerous lesions and normal control tissues. Among
all tissue types, the highest levels of let-7a were detected in
Table 2 miRNAs up-regulated (A) and down-regulated (B) in CC progression identified in more than one study
References Number of common miRNAs miRNAs
A
Li Y et al., 2011 [49]; Wilting et al., 2013 [16] 5 miR-15ba, miR-17, miR-92b,
miR-93, miR-185
Li Y et al., 2011 [49]; Pereira et al., 2010 [48]; Wilting et al., 2013 [16] 2 miR-16, miR-106a
Li Y et al., 2011 [49]; Wang et al., 2014 [34]; Wilting et al., 2013 [16] 2 miR-92a, miR-25
Deftereos et al., 2011 [33]; Shishoida et al., 2015 [37]; Wilting et al.,
2013 [16]; Zeng et al., 2015 [50]; Bumrungthai et al. 2015 [40]
1 miR-21
Cheung et al., 2012 [51]; Pereira et al., 2010 [48]; Wilting et al., 2013 [16] 1 miR-10a
Cheung et al., 2012 [51]; Li Y et al., 2011 [49]; Wilting et al., 2013 [16] 1 miR-20b
Gocze et al., 2015 [36]; Li Y et al., 2011 [49]; Wilting et al., 2013 [16] 1 miR-155
Cheung et al., 2012 [51]; Wilting et al., 2013 [16]; Zeng et al., 2015 [50] 1 miR-9
Li Y et al., 2011 [49]; Zeng et al., 2015 [50]; Zheng et al., 2015 [38] 1 miR-31
Gocze et al., 2015 [36]; Pereira et al., 2010 [48] 1 miR-27a
Wilting et al. 2015 [16]; Ma et al., 2015 [39] 1 miR-146a
Pereira et al., 2010 [48]; Villegas-Ruiz et al., 2014 [47] 1 miR-196a
B
Li Y et al., 2011 [49]; Li Y et, 2010 [31]; Tian et al., 2014 [44]; Wilting
et al., 2013 [16]; Zeng et al., 2015 [50]; Jimenez-Vences et al. 2016 [41]
1 miR-218
Bierkens et al., 2013 [52]; Li Y et al., 2011 [49]; Tian et al., 2014 [44];
Wilting et al., 2013 [16]
1 miR-375
Li Y et al., 2011 [49]; Pereira et al., 2010 [48]; Wilting et al., 2013 [16] 1 miR-99a
Li Y et al., 2011 [49]; Pereira et al., 2010 [48]; Wang et al., 2014 [34] 1 miR-29a
Cheung et al., 2012 [51]; Pereira et al., 2010 [48]; Wilting et al., 2013
[16]; Gocze et al. 2015 [36]
1 miR-203
Li Y et al., 2011 [49]; Wilting et al., 2013 [16]; Zeng et al., 2015 [50] 1 miR-195
Li Y et al., 2011 [49]; Ribeiro et al., 2015 [45]; Wilting et al., 2013 [16] 1 miR-125b
Gocze et al., 2015 [36]; Ribeiro et al., 2015 [45]; Tian et al., 2014 [44] 1 miR-34a
Li Y et al., 2011 [49]; Li. BH et al. 2011 [32]; Wilting et al., 2013 [16] 1 miR-100
Li Y et al., 2011 [49]; Pereira et al., 2010 [48] 1 miR-145
Li Y et al., 2011 [49]; Tian et al., 2014 [44] 1 miR-424
Cheung et al., 2012 [51]; Wilting et al., 2013 [16] 1 miR-193bb
Wilting et al., 2013 [16]; Zeng et al., 2015 [50] 1 miR-497
amiR-15b is also up-regulated in Wen et al. 2017 [42]
bmiR-193b is up-regulated in Jimenez-Vences et al. 2016 [41]
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Fig. 1 Venn diagram showing (A) up-regulated and (B) down-regulated miRNAs by studies that used microarrays to identify miRNAs in different
stages of CC progression
Fig. 2 Summary of dysregulated miRNAs in the whole CC progression (miRNAs resulting from multiple studies) and miRNAs associated with
progression in intermediate states of CC progression (miRNAs resulting from multiple studies are in Italics and underlined)
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pre-cancerous lesions. Authors observed that, in the cervix,
altered miR-21 and let-7a levels were strongly associated
with aberrant expression and activation of STAT3 and
might be closely linked with HPV16 infection. In this sense,
miRNAs could mediate functional links between STAT3
and other transcription factors including, NF-kB. NF-kB
pathway is an important player in the development of
cervical cancer and with STAT3 cooperatively regulates a
number of target genes including antiapoptotic and cell
cycle control genes, and genes encoding for cytokines and
chemokine [55].
Leung and colleagues observed an overexpression of
miR-135a in SCC compared to CIN1, and CIN2/3 in FFPE
samples [35]. Authors found that miR-135a regulates Wnt/
β-catenin signaling through its target genes SIAH1 and pos-
sibly APC. This may eventually cause transformation into
ICC, with miR-135a also promoting the migration, invasion
and proliferation abilities of cancer cells.
In the work of Wang et al. [34], increased levels of
miR-25, miR-92a and miR-378 were observed in
HPV-infected tissue groups in comparison with HPV
negative tissues. These results were consistent with those
obtained from HPV-infected raft tissues. Another miRNA,
miR-27a, increased its expression from normal cervical
tissues to CIN1,2,3 and ICC, in agreement with the study
of Gocze et colleagues [36] but at variance with that of
Wilting et al. [16], in which miR-27a was down-regulated
when moving from normal tissue to ICC. MiR-27a is an
oncogenic miRNA modulated by p53, E2F and c-Myc.
Both HR-HPV E6 and E7 proteins interact with c-Myc by
increasing its transcriptional activity [56]. Finally, in agree-
ment with previous observations [49], miR-29a expression
decreased from normal tissue to CIN and ICC.
The study of Li B. et al. [30] examined the expression
of pri-miR-34a, the precursor of miR-34a, in normal cer-
vical epithelium, CIN and ICC by semi-quantitative
RT-PCR. The pri-miR-34a expression was significantly
decreased in the CIN and ICC groups in comparison
with normal cervical epithelium group as a function of
grade. The reduction of pri-miR-34a expression associ-
ated with HR-HPV infection occurred before morpho-
logic abnormalities of cervical epithelium and before the
changes induced by HR-HPV E6 in the p53-dependent
pathway. Thus, authors concluded that it is plausibly an
early-onset event in ICC development and that miR-34a
and its precursor can likely be regarded as potential mo-
lecular markers for cervical screening and molecular tar-
gets for blocking ICC development.
miRNA alterations in ICC progression analyzed in
exfoliated cells
Cervical exfoliated cells are widely used in ICC screen-
ing, both for HPV testing and Pap test. Recently, their
use has been extended to miRNA analyses. To our
knowledge, the first report on miRNA detection in cer-
vical exfoliated cells was by Tian et al. in 2014 [44]. Six
candidate miRNAs, selected among those identified by
Li Y and colleagues [49], were investigated in samples
from 1021 HPV-positive women. The levels of miR-218,
miR-34a, miR-424 and miR-375 significantly decreased
with increasing severity.
Results partially confirm those previously obtained in
cervical tissue. In particular, a decrease in the levels of
miR-424 and miR-375 with higher-grade cytology was
observed, similar to that seen when moving from CIN1
to CIN3 tissues [49].
Ribeiro et al. [45] evaluated miR-34a and miR-125b
levels in cervical exfoliated cells of women with different
histology (normal epithelium with and without HPV in-
fection, Low-grade CIN, High-grade CIN and ICC). The
study revealed an increased expression of miR-125b
among women with HPV infection but normal epithelium
and a significant progressive down-regulation with in-
creasing severity of cervical lesions, reaching an 80% re-
duction in ICC. Women with normal cervix and HPV
infection had also increased miR-34a expression levels.
Despite no significant correlation with severity of cervical
lesions, its expression increased in ICC. Significantly lower
levels of miR-34a were detected also in CIN2/3 when
compared with CIN1 and in SCC when compared with
CIN2/3 (similarly to what observed in tissues by Gocze et
al. [36]). It has been observed that miR-34a is directly reg-
ulated by p53 and that HR-HPV E6 induces its inhibition
through p53 [36]. These observations confirm that
miR-34a acts as a tumor suppressive miRNA in
HPV-induced cervical transformation. This alteration in
miR-34a expression is associated with the presence of a
single or of multiple HR-HPV types.
let-7c levels were also evaluated by qPCR in cervical
exfoliated cells from women with normal epithelium or
with CIN (but no ICC) in the study by Malta and col-
leagues [46]. let-7c was progressively down-regulated in
CIN of increasing grade. No previous investigations
characterized let-7c expression during the progression of
cervical lesions to cancer. let-7c has been reported as a
probable target of p53 and its expression is induced in
response to p53 activation [46].
These few studies shows that the potential application
of miRNA detection in cervical exfoliated cells deserves
further exploration, also as an additional option for triage
of HPV-positive women in population-based screening.
Commonly identified dysregulated miRNAs: their overlap
among studies and target enrichment
The list of miRNAs found to be up- (17) or down- (13)
regulated in relation to ICC progression and repeatedly
observed among studies is reported in Table 2 and
Additional file 2: Table S1. Among over expressed
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miRNAs, one (miR-21) was found to be associated to cer-
vical carcinogenesis by five studies, nine (miR-9, miR-16,
miR-25, miR-10a, miR-20b, miR-31 miR-92a, miR-106a
and miR-155) by 3 studies and eight (miR-15b, miR-17,
miR-27a, miR-92b, miR-93, miR-146a, miR-185 and
miR-196a) by 2 studies. Among under-expressed miRNAs,
for one (miR-218) an association was found by six studies,
for two (miR-375 and miR-203) by four studies and for six
(miR-99a, miR-29a, miR-195, miR-125b, miR-34a and
miR-100) by three studies each. Fig. 1 reports the overlap
between array-based studies, which was in fact very small.
The number of experimentally validated target genes for
all the above mentioned miRNAs, retrieved in the miR-
Walk 2.0 database, is reported in Additional file 2: Table
S2. Some 16,671 target genes were identified for the
up-regulated miRNAs and 7075 for those down-regulated.
After removing multiple miRNA binding sites for each
target gene, genes overlapping within each group of miR-
NAs and those in common between up-regulated and
down-regulated miRNAs, 3395 and 1575 genes, respect-
ively, remained. Gene enrichment analysis for the final list
of target genes of down-regulated miRNAs provided sta-
tistically significant over-representation and biologically
plausible Kegg pathways terms (Additional file 2: Table
S3). Subsequently, the enrichment analysis was focused
only on the genes that were targeted by miRNAs found
up-regulated in more studies (Additional file 2: Table S4).
In this case, an overrepresentation of Kegg pathway terms
(Additional file 2: Table S5) and Virus Mint terms
emerged (Additional file 2: Table S6).
Finally, both original lists of miRNA validated target
genes were investigated also in the CCDB database,
where 257 genes over- and 110 under-expressed in ICC
are listed. Among those genes previously identified as
targets for down-regulated miRNAs (thus expected to be
over-expressed with progression to ICC), 22 (8.5%) were
indeed reported as over-expressed in ICC in CCDB. On
the other hand, among the target genes of up-regulated
miRNAs (thus expected to be under-expressed with in-
creasing severity), 34 (30.9%) were also among the genes
listed as under-expressed in ICC (Additional file 2: Table
S7). Enrichment analyses have been performed on these
resulting genes (Additional file 2: Tables S8, S9).
Discussion
In summary, the expression levels of several miRNAs were
repeatedly found to be associated to progression towards
ICC via pre-cancerous lesions in different studies (Fig. 2).
Interestingly, for many of them deregulation was not only
confirmed by an internal validation in the same study but
also with other techniques by other researchers. For in-
stance, miR29a was found to be down-regulated with ICC
progression [49] both when its expression levels were ana-
lyzed by an array-approach or tested by qPCR in an
independent set of samples. Similar observations were ob-
tained by Wang and colleagues [34], who first investigated
the same miRNA by array and validated such results by
qPCR on a large sample set.
Among up-regulated miRNAs, miR-21, which was
found associated to CIN and ICC in 4 studies [16, 33,
37, 50], is of particular interest. miR-21 is one of the
most abundantly expressed miRNA in mammals. Its
up-regulation is associated with many cancers, both de-
rived from solid tissues and of leukemic origin [57]. The
identification of miR-21 function was the object of many
research groups in the last 10 years. miR-21 interacts
with a large number of targets and it is finely regulated
in response to extracellular signals. Although miR-21
has been recognized as a key regulator of many pro-
cesses involved in the control of cell survival and prolif-
eration, it has also been linked to key processes in
inflammation. Unlike other molecules, miR-21 is not
simply characteristic of a pro-inflammatory or immuno-
suppressive status, but it acts as a key signal mediating
their balance [57, 58]. Other miRNAs found altered in
the present review, such as miR-125b, miR-155, and
miR-146a, are known to be important in immune re-
sponse and inflammation [59]. As an example, miR-125b
is repeatedly observed down-regulated in relation to ICC
progression. Interestingly, this miRNA has an important
role in immune response and inflammation but can act as
both an oncogene and oncosuppressor. miR-125b seems
to be associated with HPV-induced carcinogenesis in two
distinct pathways: a) it has homology for HPV-L2, which
is needed for the viral capsid assembly (so it is possible
that after early infection miR-125b can inhibit HPV repli-
cation and improve viral clearance); and b) miR-125b
leads to p53-pathway inactivation, thus maintaining cells
viable with viral genomes inside. This may result in the
observed increased risk of HPV-genome integration and
neoplastic lesion development [20]. To discern between
an involvement of miRNAs in inflammatory processes re-
lated to HPV infection and their role in malignant trans-
formation remains still an open issue, which needs to be
furtherly explored [40].
Among down-regulated miRNAs, miR-34a, miR-125
and miR-375 were found to be progressively dysregu-
lated when moving from normal epithelium to ICC, both
in tissues and in exfoliated cells. This finding opens the
possibility of an application in the screening process, to
be tested in larger populations. From an epidemiological
point of view, the main limitation of existing studies is
the limited number of subjects included and, even more,
in their being possibly selected. In principle, only sam-
ples including all lesions detected in a population-based
screening and a random sample of healthy women from
the same population (or of HPV-positive women without
lesions if the conclusions are to be applied to
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HPV-positive women) are not subject to selection bias.
Most studies seem, instead, to have been conducted on
convenience material, whose origin and possible selec-
tion is usually not discussed in detail.
Some miRNAs were dysregulated in all stages of car-
cinogenesis, others only when moving from CIN2/3 to
ICC [16, 36, 48, 51] (Fig. 2). In one study, miR-196 in-
creased from normal epithelium to CIN3 and then de-
creases from CIN3 to ICC [36].
When investigating the role of the experimentally vali-
dated target genes of the miRNAs identified as dysregulated
in cervical carcinogenesis, we found many pathways rele-
vant to ICC onset and progression, such as signaling path-
ways. Interestingly, the overlap between the results of
microarray-based studies was limited. This may be due to
differences in study designs and populations (i.e. different
ethnicities) or to the small number of ICC and CIN investi-
gated. However, we must also report that all studies used
different arrays, thus containing different number and type
of miRNA probes or based on different array technology.
The most interesting miRNAs found as dysregulated in
multiple studies include miR-10a [16, 48, 51], miR-20b [16,
49, 51], miR-9 [16, 50, 51], miR-16 and miR-106a [16, 48,
49] (all up-regulated) and miR-99a [16, 48, 49], miR-203
[16, 48, 51], and miR-195 [16, 49, 50] (down-regulated).
Array-based analysis is restricted to miRNA molecules
provided by databases and suffers from
cross-detection-prone hybridization methods. As we could
notice in the present review, despite the rapidly increasing
number of miRNAs discovered and registered (currently
2656 human mature miRNAs; http://www.mirbase.org/
index.shtml, Release 22 March 2018) the majority of studies
focused on the first 800 miRNAs. Recently the use of
next-generation sequencing (NGS) technology for miRNA
expression profiling increased [60]. NGS offers a
genome-wide approach and allows overcoming cross
hybridization problems. Small RNA-sequencing, allowing
also the detection of other similar small noncoding RNAs
(such as piRNAs and tRNAs), has the greatest detection
sensitivity and the highest accuracy in differential expres-
sion analysis. For the application of NGS techniques to
small RNAs the standardization of experimental and com-
putational protocols just begun [61]. Nevertheless, an im-
portant increase of studies applying NGS to miRNAs, also
in cervical carcinogenesis, is expected in the next future
[62]. The ideal approach would be to apply NGS on
homogenous large scale studies for an hypothesis-free in-
vestigation of the whole miRNome to detect robust poten-
tial candidate (s) miRNA relevant for ICC progression as
well as high-risk HPV infection. This is to avoid conflicting
outcomes from small studies analyzing restricted lists of
candidate miRNAs. Finally, small specific miRNA signa-
tures should be evicted to be applied on a very extended
scale, also in countries with more limited availability of
funds for molecular analyses in the clinical routine. The
first molecular characterization, including miRNAs, of 228
primary cervical cancers in comparison with healthy tissues
has been recently described by The Cancer Genome Atlas
(TCGA) network [63].
Conclusions
In the context of ICC screening, an important issue to
be investigated is whether miRNA signatures could be
associated with current and future risk of HG-CIN, most
likely in combination with other different markers, in
order to improve risk stratification. Some of these
markers could be used to identify very recently arisen
HG-CIN. As the latter have very low probability of pro-
gression to invasion in short time and high probability
of regression, this would allow a “wait and see” manage-
ment, resulting in reduced overtreatment. The investiga-
tion of miRNA levels in cervical exfoliated cells certainly
opens new possibilities for studying molecular markers
in the context of screening programs.
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